See more : Glenmark Life Sciences Limited (GLS.NS) Income Statement Analysis – Financial Results
Complete financial analysis of ODI Pharma AB (ODI.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ODI Pharma AB, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- The Kraft Heinz Company (KHC) Income Statement Analysis – Financial Results
- The Kansai Electric Power Company, Incorporated (KAEPY) Income Statement Analysis – Financial Results
- Cosmo Electronics Corporation (2466.TW) Income Statement Analysis – Financial Results
- Periphas Capital Partnering Corporation (PCPC-UN) Income Statement Analysis – Financial Results
- Bufab AB (publ) (BUFAB.ST) Income Statement Analysis – Financial Results
ODI Pharma AB (ODI.ST)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.odipharma.com
About ODI Pharma AB
ODI Pharma AB (publ), a pharmaceutical company, produces and distributes pharmaceutical cannabis and cosmetics products in Europe. The company offers cannabidiol-infused facial cream, facial mask, and body balm under the Kandol. brand name through kandol.net. The company was founded in 2018 and is based in Stockholm, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 22.45M | 139.46K | 312.94K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 23.79M | 6.58M | 7.54M | 6.98K | 12.26K | 2.10K |
| Gross Profit | -1.34M | -6.44M | -7.23M | -6.98K | -12.26K | -2.10K |
| Gross Profit Ratio | -5.98% | -4,616.29% | -2,310.39% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 3.25M | 4.70M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 670.22K | 0.00 | 0.00 |
| SG&A | -5.00 | 375.00K | 0.00 | 3.92M | 4.70M | 3.46M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -5.00 | 375.00K | 7.10M | 3.92M | 4.70M | 3.46M |
| Cost & Expenses | 23.79M | 6.95M | 7.54M | 3.93M | 4.72M | 3.46M |
| Interest Income | 145.06K | 23.91K | 133.00 | 11.49K | 18.00 | 29.00 |
| Interest Expense | 819.87K | 107.67K | 28.76K | 14.57K | 7.80K | 8.92K |
| Depreciation & Amortization | 3.10K | 4.11K | 5.59K | 6.98K | 12.26K | 2.10K |
| EBITDA | 478.65K | -6.89M | -7.20M | -3.96M | -4.92M | -3.34M |
| EBITDA Ratio | 2.13% | -4,882.24% | -2,308.61% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.34M | -6.81M | -7.23M | -3.93M | -4.72M | -3.46M |
| Operating Income Ratio | -5.98% | -4,885.19% | -2,310.39% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.89M | -82.38K | -5.43K | -42.09K | -225.73K | 110.45K |
| Income Before Tax | 544.56K | -6.90M | -7.24M | -3.97M | -4.94M | -3.35M |
| Income Before Tax Ratio | 2.43% | -4,944.26% | -2,312.13% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 188.59K | 6.02K | 3.51K | 14.37K | 20.05K | 282.86K |
| Net Income | 355.97K | -6.90M | -7.24M | -3.98M | -4.96M | -3.63M |
| Net Income Ratio | 1.59% | -4,948.58% | -2,313.25% | 0.00% | 0.00% | 0.00% |
| EPS | 0.02 | -0.45 | -0.48 | -0.26 | -0.33 | -0.24 |
| EPS Diluted | 0.02 | -0.45 | -0.48 | -0.26 | -0.33 | -0.24 |
| Weighted Avg Shares Out | 15.25M | 15.22M | 15.22M | 15.22M | 15.22M | 15.22M |
| Weighted Avg Shares Out (Dil) | 15.25M | 15.22M | 15.22M | 15.22M | 15.22M | 15.22M |
Source: https://incomestatements.info
Category: Stock Reports